Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology

Despite their great success, we understand little about how effective vaccines stimulate protective immune responses. Two recent developments promise to yield such understanding: the appreciation of the crucial role of the innate immune system in sensing microorganisms and tuning immune responses, and advances in systems biology. Here I review how these developments are yielding insights into the mechanism of action of the yellow fever vaccine, one of the most successful vaccines ever developed, and the broader implications for vaccinology.

[1]  Max Theiler,et al.  THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION , 1937, The Journal of experimental medicine.

[2]  A. Barrett,et al.  Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? , 2009, Current opinion in immunology.

[3]  A. Prata.  Yellow fever. , 2000, Memorias do Instituto Oswaldo Cruz.

[4]  M. Cetron,et al.  Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. , 2008, The Journal of infectious diseases.

[5]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[6]  N. Sonenberg,et al.  Regulation of cap-dependent translation by eIF4E inhibitory proteins , 2005, Nature.

[7]  B. Pulendran,et al.  Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease , 2007, Vaccine.

[8]  E. Hindle,et al.  A YELLOW FEVER VACCINE , 1928, British medical journal.

[9]  Robert T. Chen,et al.  Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. , 2005, Vaccine.

[10]  A. Barrett,et al.  Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. , 1997, Virology.

[11]  Osamu Takeuchi,et al.  Innate immunity to virus infection , 2009, Immunological reviews.

[12]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[13]  A. Rothman,et al.  Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. , 2002, Virology.

[14]  A. Keating,et al.  Functional properties and genomics of glucose transporters. , 2007, Current genomics.

[15]  R. Kaufman.  coordination of gene transcriptional and translational controls Stress signaling from the lumen of the endoplasmic reticulum , 2008 .

[16]  R. Woodland,et al.  BLyS and B cell homeostasis. , 2006, Seminars in immunology.

[17]  A. Sabin.  Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.

[18]  Bali Pulendran,et al.  Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity , 2006, The Journal of experimental medicine.

[19]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Teixeira-Carvalho,et al.  Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. , 2008, Vaccine.

[21]  T. Mizutani,et al.  Different chemokine expression in lethal and non‐lethal murine west nile virus infection , 2004, Journal of medical virology.

[22]  A. Luster,et al.  Dengue Virus Induces Expression of CXC Chemokine Ligand 10/IFN-γ-Inducible Protein 10, Which Competitively Inhibits Viral Binding to Cell Surface Heparan Sulfate1 , 2006, The Journal of Immunology.

[23]  Á. L. Bertho,et al.  Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. , 2008, Cytokine.

[24]  Ken Draper,et al.  Single Mutation in the Flavivirus Envelope Protein Hinge Region Increases Neurovirulence for Mice and Monkeys but Decreases Viscerotropism for Monkeys: Relevance to Development and Safety Testing of Live, Attenuated Vaccines , 2002, Journal of Virology.

[25]  J. Altman,et al.  Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. , 2008, Immunity.

[26]  B. Pulendran.  Variegation of the Immune Response with Dendritic Cells and Pathogen Recognition Receptors1 , 2005, The Journal of Immunology.

[27]  Bastian R. Angermann,et al.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.

[28]  P. Anderson,et al.  Mammalian stress granules and processing bodies. , 2007, Methods in enzymology.

[29]  Virginia Pascual,et al.  A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. , 2008, Immunity.

[30]  H. Dressman,et al.  Genomic signatures to guide the use of chemotherapeutics , 2006, Nature Medicine.

[31]  B. Pulendran,et al.  Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway , 2008, Nature Immunology.

[32]  K. Popper,et al.  Conjectures and Refutations , 1963 .

[33]  F. Guirakhoo,et al.  Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. , 2001, Virology.

[34]  Matthias Niedrig,et al.  Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection , 1998, Journal of medical virology.

[35]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[36]  D. Teuwen,et al.  Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. , 2008, The Journal of infectious diseases.

[37]  D. Sabatini,et al.  Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.

[38]  S. Akira,et al.  The RNA Helicase Lgp2 Inhibits TLR-Independent Sensing of Viral Replication by Retinoic Acid-Inducible Gene-I1 , 2005, The Journal of Immunology.

[39]  P. Walter,et al.  Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.

[40]  J. H. Strauss,et al.  Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Hugh H. Smith,et al.  THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS , 1937, The Journal of experimental medicine.

[42]  J. Banchereau,et al.  Gene expression patterns in blood leukocytes discriminate patients with acute infections. , 2007, Blood.

[43]  F. Guirakhoo,et al.  A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys , 2004, Journal of Virology.

[44]  N. Sonenberg,et al.  Antiviral effect of the mammalian translation initiation factor 2α kinase GCN2 against RNA viruses , 2006, The EMBO journal.

[45]  Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain. , 1996, The Journal of general virology.

[46]  S. Fernandez,et al.  Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. , 2007, The Journal of general virology.

[47]  B. Dixon.  Microbe Hunters—Then and Now , 1996 .

[48]  C. Rice,et al.  Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes , 2005, The Journal of experimental medicine.